NEW YORK (TheStreet) -- Eli Lilly shares are down 1.87% to $69.27 in early market trading on Friday after a German court ruled against it in a patent case involving its Alimta lung cancer drug.The court ruled that generic drug maker Actavis would not infringe on the company's patent by marketing an alternative salt form of the Alimta, known as pemetrexed, once the drug's compound patent expires at the end of this year."We strongly disagree with the ruling by the German Court of Appeal regarding Alimta's vitamin regimen patent," said the company's senior VP and general counsel Michael J.